Biotechnology

BTBP

BTBP released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 1.142 B (forecast CNY 1.334 B), actual EPS CNY 0.06 (forecast CNY 0.1235)

BTBP to Release FY2026 Q1 Earnings on April 30 After-Market (BJT), Forecast Revenue CNY 1.334 B, EPS CNY 0.1235

BTBP released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue CNY 1.703 B (forecast CNY 2.157 B), actual EPS CNY 0.14 (forecast CNY 0.2538)

BTBP released FY2025 Annual Earnings on March 27 After-Market (BJT), actual revenue CNY 6.168 B (forecast CNY 6.559 B), actual EPS CNY 0.55 (forecast CNY 0.6843)

BTBP to release FY2025 earnings on March 28 After-Market (BJT), forecast revenue CNY 6.559 B, EPS CNY 0.6843

BTBP released FY2025 9 Months earnings on October 24 Pre-Market (BJT), actual revenue CNY 4.465 B, actual EPS CNY 0.4137

BTBP released FY2025 Q3 earnings on October 24 Pre-Market (BJT), actual revenue CNY 1.355 B (forecast CNY 1.369 B), actual EPS CNY 0.0913 (forecast CNY 0.1649)

BTBP to release FY2025 Q3 earnings on October 25 Pre-Market (BJT), forecast revenue CNY 1.369 B, EPS CNY 0.1649

BTBP to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Tiantan Bio Reports Revenue Growth and Net Profit Decline in H1 2025

BTBP released FY2025 Semi-Annual earnings on August 6 During-Market BJT, actual revenue CNY 3.11 B, actual EPS CNY 0.32

BTBP released FY2025 Q2 earnings on August 6 During-Market (BJT), actual revenue CNY 1.793 B (forecast CNY 1.654 B), actual EPS CNY 0.2024 (forecast CNY 0.193)

Tiantan Bio's Subsidiary Chengdu Rongsheng Receives Supplemental Approval for Intravenous Immune Globulin

Chengdu Rongsheng Blood Products Workshop Passes GMP Compliance Inspection

Tiantan Bio Responds to Investor Concerns Over Imported Blood Products Dependency

Tiantan Biologics Progressing in Restoring Xi'an Blood Production

Tiantan Biologics' Strategies to Deal with Intensified Industry Competition

Tiantan Bio Secretary Responds to 2025 Performance and Product Price Stability

Tiantan Biologics' Net Profit Down 22.90% in Q1

Tiantan Biologics Announces Significant Net Profit Growth in 2024 Annual and First Quarter Reports

600161

BTBP announced that the 26th meeting of the 9th Board of Directors held on October 23, 2025, reviewed several proposals. First, it approved the "Q3 2025 Report"; second, it agreed to abolish the Blood Source Management Center and establish the Blood Source Management Department and Blood Source Management Region; third, it agreed that its subsidiary, TianTan Wuhan, would acquire 1% equity of Songzi Plasma Station for 222,660 yuan, after which it will hold 100% equity; fourth, it approved the proposal to authorize the general manager's office to make decisions on pre-approval matters related to economic activities

Zhitong

BTBP: Reviewed the third quarterly report, adjusted the structure, and acquired 1% equity in Songzi Pulp Station

BTBP announced that its subsidiary has officially launched the Phase III clinical trial of human prothrombin complex, which is used to treat various coagulation factor deficiencies. Although similar products are already available in domestic and international markets, this product still needs to complete clinical trials and market application, and investors should be aware of the associated risks

BTBP: Recently officially launched Phase III clinical trials for human prothrombin complex

BTBP announced that its subsidiary TianTan Kunming has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen." This product must complete clinical trials, submit a market application, and pass relevant reviews and approval processes before it can be produced and sold on the market

BTBP: Tiantan Kunming has been approved to conduct clinical trials for "human fibrinogen"

According to the Zhitong Finance APP, BTBP announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as "Chengdu Rongsheng") has received the "Drug GMP Compliance Inspection Notification" issued by the Sichuan Provincial Drug Administration, involving the workshop for: recombinant product production workshop

BTBP's subsidiary received a notice of compliance inspection for drug GMP

Beijing BTBP Biotechnology Co., Ltd. announced the implementation of the 2025 semi-annual equity distribution, deciding to distribute a cash dividend of RMB 0.15 per share, totaling RMB 296,605,716.90. The equity registration date is September 24, 2025, and the ex-dividend date and cash dividend payment date is September 25. The tax deduction policies for different types of shareholders vary; individual shareholders holding shares for more than 1 year are temporarily exempt from personal income tax, while QFIIs are taxed at 10%

Beijing BTBP 2025 Half-Year Equity Distribution Implementation Announcement Released

According to the Zhitong Finance APP, BTBP released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 3.11 billion yuan, a year-on-year increase of 9.47%. The net profit attributable to shareholders of the listed company was 633 million yuan, a year-on-year decrease of 12.88%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 618 million yuan, a year-on-year decrease of 14.54%. The basic earnings per share were 0.32 yuan

BTBP released its performance for the first half of the year, with a net profit attributable to the parent company of 633 million yuan, a year-on-year decrease of 12.88%

In the first half of 2025, BTBP's net profit attributable to the parent company was 633 million yuan, a year-on-year decrease of 12.88%. Although total operating revenue reached 3.11 billion yuan, a year-on-year increase of 9.47%, the decline in net profit was due to a decrease in product sales prices and changes in credit policies leading to reduced interest income

BTBP's net profit attributable to the parent company in the first half of the year was 633 million yuan, a year-on-year decrease of 12.88%

000403

First, the major shareholder takes action

Wallstreetcn

PLBIO

The Mystery of BTBP "Refusing" PLBIO

BTBP announced the abandonment of the acquisition opportunity for PLBIO, as the blood product business involved in the transaction poses a competitive conflict with its main business. The controlling shareholder China National Biological has formally notified BTBP in writing about this business opportunity based on the commitment letter to avoid competition. In the future, China National Biological will implement the acquisition of PLBIO from the perspective of overall development strategy and will make further commitments regarding the issue of competition after completion

BTBP plans to abandon the acquisition of PLBIO business opportunity

The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limit, WanZe Co., Ltd. previously sealing the board, and Eddie Pharmaceuticals, IM Motors, Boya Bio, Bohui Innovation, PLBIO, and others following suit

BTBP(600161.SH)